NCT02917707 Integrative Analysis of CRC Liver Metastasis
| NCT ID | NCT02917707 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Da Fu |
| Condition | Metastasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will perform integrative analysis of CRC liver metastasis
Eligibility Criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven CRC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * World Health Organization (WHO) performance status of \>1 * Prior cancer chemotherapy
Contact & Investigator
Da Fu, Ph.D.
PRINCIPAL INVESTIGATOR
the Shanghai Tenth People's Hospital
Frequently Asked Questions
Who can join the NCT02917707 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02917707 currently recruiting?
Yes, NCT02917707 is actively recruiting participants. Contact the research team at shsyiec@126.com for enrollment information.
Where is the NCT02917707 trial being conducted?
This trial is being conducted at Ganzhou, China, Shanghai, China.
Who is sponsoring the NCT02917707 clinical trial?
NCT02917707 is sponsored by Da Fu. The principal investigator is Da Fu, Ph.D. at the Shanghai Tenth People's Hospital. The trial plans to enroll 1,000 participants.